Metabolic signatures of human Alzheimer’s disease (AD): 1H NMR analysis of the polar metabolome of post-mortem brain tissue

Metabolomics ◽  
2013 ◽  
Vol 10 (4) ◽  
pp. 744-753 ◽  
Author(s):  
Stewart F. Graham ◽  
Christian Holscher ◽  
Brian D. Green
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Brain Tissue ◽  
1H Nmr ◽  
Post Mortem ◽  
Nmr Analysis ◽  
Post Mortem Brain ◽  
Metabolic Signatures

P1-155: Post-Mortem Brain Tissue Characterisation of Inflammatory and Pathological Hallmarks of Alzheimer’s Disease During Disease Progression

2016 ◽  
Vol 12 ◽  
pp. P462-P462
Author(s):  
Martina M. Hughes ◽  
Beatriz G. Perez-Nievas ◽  
Claire Troakes ◽  
Michael Perkinton ◽  
Diane P. Hanger ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Progression ◽  
Brain Tissue ◽  
Post Mortem ◽  
Tissue Characterisation ◽  
Post Mortem Brain

scholarly journals Natriuretic Peptides in Post-mortem Brain Tissue and Cerebrospinal Fluid of Non-demented Humans and Alzheimer’s Disease Patients

2018 ◽  
Vol 12 ◽  
Author(s):  
Simin Mahinrad ◽  
Marjolein Bulk ◽  
Isabelle van der Velpen ◽  
Ahmed Mahfouz ◽  
Willeke van Roon-Mom ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Brain Tissue ◽  
Natriuretic Peptides ◽  
Post Mortem ◽  
Post Mortem Brain

scholarly journals Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype

2010 ◽  
Vol 16 (8) ◽  
pp. 836-847 ◽  
Author(s):  
C Conejero-Goldberg ◽  
T M Hyde ◽  
S Chen ◽  
U Dreses-Werringloer ◽  
M M Herman ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
High Risk ◽  
Brain Tissue ◽  
Apoe Genotype ◽  
Molecular Signatures ◽  
Post Mortem ◽  
Post Mortem Brain

P1-071: Molecular signatures in post mortem brain tissue of individuals at high risk for Alzheimer's disease

2010 ◽  
Vol 6 ◽  
pp. S194-S194 ◽  
Author(s):  
Concepcion Conejero-Goldberg ◽  
Thomas M. Hyde ◽  
Shufen Chen ◽  
Ute Dreses-Werringloer ◽  
Mary M. Herman ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
High Risk ◽  
Brain Tissue ◽  
Molecular Signatures ◽  
Post Mortem ◽  
Post Mortem Brain

scholarly journals Luminex-based quantification of Alzheimer’s disease neuropathologic change in formalin-fixed post-mortem human brain tissue

2018 ◽  
Vol 99 (7) ◽  
pp. 1056-1067
Author(s):  
C. Dirk Keene ◽  
Angela M. Wilson ◽  
Mitchell D. Kilgore ◽  
Lauren T. Bruner ◽  
Nadia O. Postupna ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Human Brain ◽  
Brain Tissue ◽  
Post Mortem ◽  
Human Brain Tissue ◽  
Formalin Fixed

Genome-wide profiling and predicted significance of post-mortem brain microRNA in Alzheimer’s disease

2020 ◽  
Vol 191 ◽  
pp. 111352
Author(s):  
Adriane D. Henriques ◽  
Wilcelly Machado-Silva ◽  
Renata E.P. Leite ◽  
Claudia K. Suemoto ◽  
Kátia R.M. Leite ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Post Mortem ◽  
Genome Wide ◽  
Post Mortem Brain

scholarly journals Platelet phosphorylated TDP-43: An exploratory study for a peripheral surrogate biomarker development for Alzheimer’s disease

2017 ◽  
Author(s):  
Rodger Wilhite ◽  
Jessica Sage ◽  
Abdurrahman Bouzid ◽  
Tyler Primavera ◽  
Abdulbaki Agbas
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Early Stage ◽  
Clinical Signs ◽  
Brain Regions ◽  
Post Mortem ◽  
Disease Prognosis ◽  
Post Mortem Brain ◽  
And Control ◽  
Lateral Sclerosis

AbstractAim: Alzheimer’s disease (AD) and other forms of dementia create a non-curable disease population in World’s societies. To develop a blood-based biomarker is important so that the remedial or disease-altering therapeutic intervention for AD patients would be available at the early stage. Materials & Methods: TDP-43 levels were analyzed in post-mortem brain tissue and platelets of AD and control subjects. Results: We observed an increased TDP-43 (<60%) in post-mortem AD brain regions and similar trends were also observed in patient’s platelets. Conclusion: Platelet TDP-43 could be used as a surrogate biomarker that is measurable, reproducible, and sensitive for screening the patients with some early clinical signs of AD and can be used to monitor disease prognosis.Lay abstractIn this study, we explore to identify an Alzheimer’s disease-selective phospho-specific antibody that recognizes the diseased form of TDP-43 protein in patient’s blood-derived platelets. Our results suggest that selective anti-phosphorylated TDP-43 antibody discriminates Alzheimer’s disease from non-demented controls and patients with amyotrophic lateral sclerosis. Therefore, platelet screening with a selective antibody could potentially be a useful tool for diagnostic purposes for Alzheimer’s disease.

Sign in / Sign up

Export Citation Format

Share Document